Quarterly ResultMay 13, 2026, 07:31 AM
Milestone Pharma Q1 Net Loss $26.1M; CARDAMYST Launch Progress
AI Summary
Milestone Pharmaceuticals reported a net loss of $26.1 million for Q1 2026, compared to a $20.8 million loss in the prior year, with product revenues of $0.2 million from the recent CARDAMYST launch. The company secured Express Scripts national formulary coverage for CARDAMYST, which is gaining traction with approximately 600 scripts filled and 400 unique prescribers. Milestone also initiated a Phase 3 registrational trial for etripamil in AFib-RVR and maintains a strong balance sheet of $184.2 million, providing a runway into H2 2027.
Key Highlights
- Net loss for Q1 2026 was $26.1 million, compared to $20.8 million in Q1 2025.
- Product revenues for Q1 2026 were $0.2 million, up from $0 in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $184.2 million as of March 31, 2026.
- CARDAMYST launch saw ~600 scripts filled for 560 patients through April.
- Secured Express Scripts national formulary coverage for CARDAMYST.
- Initiated Phase 3 registrational trial for etripamil in AFib-RVR.
- Commercial expense rose to $15.8 million from $10.4 million YoY.
Price Impact
More from MIST